These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. Rao M; Bray M; Alving CR; Jahrling P; Matyas GR J Virol; 2002 Sep; 76(18):9176-85. PubMed ID: 12186901 [TBL] [Abstract][Full Text] [Related]
23. Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice. Li W; Ye L; Carrion R; Mohan GS; Nunneley J; Staples H; Ticer A; Patterson JL; Compans RW; Yang C J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S398-403. PubMed ID: 25877553 [TBL] [Abstract][Full Text] [Related]
24. Evaluation in nonhuman primates of vaccines against Ebola virus. Geisbert TW; Pushko P; Anderson K; Smith J; Davis KJ; Jahrling PB Emerg Infect Dis; 2002 May; 8(5):503-7. PubMed ID: 11996686 [TBL] [Abstract][Full Text] [Related]
25. Development of vaccines for prevention of Ebola virus infection. Ye L; Yang C Microbes Infect; 2015 Feb; 17(2):98-108. PubMed ID: 25526819 [TBL] [Abstract][Full Text] [Related]
26. VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection. Williams KJ; Qiu X; Fernando L; Jones SM; Alimonti JB Viral Immunol; 2015 Feb; 28(1):51-61. PubMed ID: 25494457 [TBL] [Abstract][Full Text] [Related]
27. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. Lai L; Davey R; Beck A; Xu Y; Suffredini AF; Palmore T; Kabbani S; Rogers S; Kobinger G; Alimonti J; Link CJ; Rubinson L; Ströher U; Wolcott M; Dorman W; Uyeki TM; Feldmann H; Lane HC; Mulligan MJ JAMA; 2015 Mar 24-31; 313(12):1249-55. PubMed ID: 25742465 [TBL] [Abstract][Full Text] [Related]
28. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys. Skiadopoulos MH; Surman SR; Riggs JM; Collins PL; Murphy BR J Virol; 2001 Nov; 75(21):10498-504. PubMed ID: 11581420 [TBL] [Abstract][Full Text] [Related]
29. Recent advances in the development of vaccines for Ebola virus disease. Ohimain EI Virus Res; 2016 Jan; 211():174-85. PubMed ID: 26596227 [TBL] [Abstract][Full Text] [Related]
30. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Pushko P; Bray M; Ludwig GV; Parker M; Schmaljohn A; Sanchez A; Jahrling PB; Smith JF Vaccine; 2000 Aug; 19(1):142-53. PubMed ID: 10924796 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies. Durbin AP; Cho CJ; Elkins WR; Wyatt LS; Moss B; Murphy BR J Infect Dis; 1999 Jun; 179(6):1345-51. PubMed ID: 10228053 [TBL] [Abstract][Full Text] [Related]
32. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831 [TBL] [Abstract][Full Text] [Related]
33. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. Jones SM; Stroher U; Fernando L; Qiu X; Alimonti J; Melito P; Bray M; Klenk HD; Feldmann H J Infect Dis; 2007 Nov; 196 Suppl 2():S404-12. PubMed ID: 17940977 [TBL] [Abstract][Full Text] [Related]
34. Experimental Respiratory Infection of Marmosets (Callithrix jacchus) With Ebola Virus Kikwit. Smither SJ; Nelson M; Eastaugh L; Nunez A; Salguero FJ; Lever MS J Infect Dis; 2015 Oct; 212 Suppl 2():S336-45. PubMed ID: 26209682 [TBL] [Abstract][Full Text] [Related]
35. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. Gupta M; Mahanty S; Bray M; Ahmed R; Rollin PE J Virol; 2001 May; 75(10):4649-54. PubMed ID: 11312335 [TBL] [Abstract][Full Text] [Related]
36. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Martin JE; Sullivan NJ; Enama ME; Gordon IJ; Roederer M; Koup RA; Bailer RT; Chakrabarti BK; Bailey MA; Gomez PL; Andrews CA; Moodie Z; Gu L; Stein JA; Nabel GJ; Graham BS Clin Vaccine Immunol; 2006 Nov; 13(11):1267-77. PubMed ID: 16988008 [TBL] [Abstract][Full Text] [Related]
37. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Sun Y; Carrion R; Ye L; Wen Z; Ro YT; Brasky K; Ticer AE; Schwegler EE; Patterson JL; Compans RW; Yang C Virology; 2009 Jan; 383(1):12-21. PubMed ID: 18986663 [TBL] [Abstract][Full Text] [Related]
38. Towards a vaccine against Ebola virus. Geisbert TW; Jahrling PB Expert Rev Vaccines; 2003 Dec; 2(6):777-89. PubMed ID: 14711361 [TBL] [Abstract][Full Text] [Related]